IRIS
ARMENI, PATRIZIO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 9.791
NA - Nord America 6.813
AS - Asia 3.302
SA - Sud America 367
Continente sconosciuto - Info sul continente non disponibili 273
AF - Africa 96
OC - Oceania 24
Totale 20.666
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 6.512
IT - Italia 3.569
RU - Federazione Russa 1.914
FI - Finlandia 1.023
CN - Cina 1.022
GB - Regno Unito 864
SG - Singapore 831
IE - Irlanda 719
UA - Ucraina 349
DE - Germania 347
VN - Vietnam 344
FR - Francia 290
BR - Brasile 289
HK - Hong Kong 227
CA - Canada 223
SE - Svezia 173
TR - Turchia 161
NL - Olanda 151
IN - India 141
KR - Corea 127
BD - Bangladesh 120
CZ - Repubblica Ceca 61
PL - Polonia 56
ID - Indonesia 51
BG - Bulgaria 50
ZA - Sudafrica 50
ES - Italia 49
IL - Israele 45
BE - Belgio 43
MX - Messico 43
IQ - Iraq 32
JP - Giappone 31
AR - Argentina 30
AT - Austria 28
CH - Svizzera 23
PK - Pakistan 22
AU - Australia 19
AE - Emirati Arabi Uniti 16
CO - Colombia 16
IR - Iran 16
RO - Romania 14
DK - Danimarca 12
MA - Marocco 11
PH - Filippine 11
TH - Thailandia 11
UZ - Uzbekistan 11
CL - Cile 10
MY - Malesia 10
EC - Ecuador 9
PT - Portogallo 9
TW - Taiwan 9
EU - Europa 8
GR - Grecia 8
JO - Giordania 8
HN - Honduras 7
PA - Panama 7
SA - Arabia Saudita 7
AM - Armenia 6
AZ - Azerbaigian 6
GE - Georgia 6
KE - Kenya 6
LT - Lituania 6
LV - Lettonia 6
CR - Costa Rica 5
EG - Egitto 5
HU - Ungheria 5
NZ - Nuova Zelanda 5
TN - Tunisia 5
VE - Venezuela 5
JM - Giamaica 4
KG - Kirghizistan 4
KZ - Kazakistan 4
LA - Repubblica Popolare Democratica del Laos 4
SI - Slovenia 4
DZ - Algeria 3
NO - Norvegia 3
PE - Perù 3
PS - Palestinian Territory 3
SN - Senegal 3
AL - Albania 2
BB - Barbados 2
BO - Bolivia 2
BY - Bielorussia 2
BZ - Belize 2
CG - Congo 2
EE - Estonia 2
GT - Guatemala 2
LB - Libano 2
LK - Sri Lanka 2
LU - Lussemburgo 2
MD - Moldavia 2
NG - Nigeria 2
OM - Oman 2
PY - Paraguay 2
SV - El Salvador 2
SY - Repubblica araba siriana 2
UG - Uganda 2
A1 - Anonimo 1
A2 - ???statistics.table.value.countryCode.A2??? 1
AD - Andorra 1
Totale 20.379
Salva come PNG Salva come JPEG
Città #
Helsinki 957
San Jose 871
Ashburn 812
Milan 761
Dublin 717
Southend 532
Chandler 484
Singapore 436
Dallas 376
Moscow 356
Hefei 353
Rome 300
Jacksonville 277
Council Bluffs 274
Ann Arbor 234
Beijing 233
Hong Kong 222
New York 179
The Dalles 156
Toronto 154
Los Angeles 143
Dearborn 128
Seoul 125
Houston 109
Dong Ket 104
Edison 93
Ho Chi Minh City 90
Columbus 87
Boston 80
Wilmington 80
Lauterbourg 75
Naples 75
Modena 70
Boardman 65
Lawrence 64
Munich 60
Bologna 59
Izmir 56
Turin 55
Bari 52
Hanoi 48
Buffalo 47
Johannesburg 46
Florence 44
Frankfurt am Main 43
Jakarta 41
Redwood City 41
São Paulo 41
Warsaw 41
Catania 40
Tel Aviv 40
Brussels 39
Redmond 39
Santa Clara 38
Seattle 38
Orem 36
Genoa 34
Mountain View 34
London 33
Woodbridge 33
Assago 32
Chennai 32
Amsterdam 30
Casorate Primo 30
Montreal 30
Brooklyn 29
Tokyo 27
Cagliari 26
Chicago 24
Phoenix 24
Falkenstein 23
Palermo 21
Brescia 20
Atlanta 19
Lappeenranta 19
Brno 18
Denver 18
Duncan 18
Kunming 18
Mexico City 18
Nanjing 18
Poplar 16
Washington 16
Busto Arsizio 15
Paris 15
Pescara 15
Pisa 15
Stockholm 15
Verona 15
Parma 14
Baghdad 13
Palombara Sabina 13
Torino 13
Venice 13
Bonndorf 12
Kocaeli 12
Monza 12
Rio de Janeiro 12
Vienna 12
Ankara 11
Totale 11.903
Salva come PNG Salva come JPEG
Nome #
Digitalizzazione nelle tecnologie per la salute: impatto sui livelli di governo del SSN 726
Prezzi di riferimento per dispositivi medici: criticità, vantaggi e approcci 465
The cost of patients with chronic kidney failure before dialysis: results from the IRIDE observational study 458
Politiche del farmaco ed impatto sulla spesa: gli effetti di quindici anni di decentramento nel SSN, con un focus sull’adozione di forme alternative di distribuzione dei farmaci 433
La copertura vaccinale nelle regioni italiane. Un’analisi dell’eterogeneità 420
Dinamiche economiche e performance del settore dei dispositivi medici in Italia 392
Cost-benefit analysis in health care: the case of bariatric surgery compared with diet 379
Report n. 42 OSFAR (Osservatorio Farmaci) 372
La spesa sanitaria: composizione ed evoluzione 371
I dispositivi medici in Italia: un settore, tanti mercati 349
PDTA per la chirurgia bariatrica: l'esperienza di 6 centri italiani 329
De innovatione: the concept of innovation for medical technologies and its implications for healthcare policy-making 319
Cost-effectiveness and net monetary benefit of durvalumab consolidation therapy versus no consolidation therapy after chemoradiotherapy in stage III non–small cell lung cancer in the Italian National Health Service 316
La rendicontazione e la remunerazione dei farmaci. Finalità, struttura e gestione del File F in nove Regioni italiane 313
Market access management by pharmaceutical companies in a complex environment: the Italian case study 306
Il governo dell'assistenza farmaceutica in Italia: possibili traiettorie di cambiamento 305
Il confronto dei sistemi sanitari in una prospettiva internazionale 300
L'acquisto di farmaci in Italia: l'effetto di approcci selettivi 299
Cost-minimization analysis to support the HTA of Radiofrequency Echographic Multi Spectrometry (REMS) in the diagnosis of osteoporosis 293
Establishing a national HTA program for medical devices in Italy: overhauling a fragmented system to ensure value and equal access to new medical technologies 277
The future of Funds for Innovative Medicines: results from a Delphi Study 276
Cost-utility analysis of esketamine for patients with treatment resistant depression in Italy 273
Diffusion without evidence: a study on high-risk medical devices 269
A value-based revolution in health care: perspectives, challenges, and emerging approaches to defining and measuring the value of health care technologies 263
Il governo regionale dell'assistenza farmaceutica e il suo impatto sulla spesa 262
La spesa sanitaria: composizione ed evoluzione 262
Real-world cost effectiveness of MitraClip combined with medical therapy versus medical therapy alone in patients with moderate or severe mitral regurgitation 260
Comparative effectiveness of Mitraclip plus medical therapy versus medical therapy alone in high-risk surgical patients: a comprehensive review 258
Collecting physicians' preferences on medical devices: are we doing it right? Evidence from Italian orthopedists using 2 different stated preference methods 254
PHP3 the simultaneous effects of pharmaceutical policies from payers' and patients' perspectives: Italy as a case study 253
Digital Twins in healthcare: is it the beginning of a new era of evidence-based medicine? A critical review 250
Programma Nazionale di HTA per dispositivi medici: prove tecniche di implementazione 248
L'adozione dell'innovazione tecnologica da parte degli ospedali italiani: un'analisi dei fattori endogeni 243
Programmi di early access dei farmaci e managed entry agreement in Italia: i risultati di un Focus Group (programmi di early access e managed entry agreement) 243
Il confronto dei sistemi sanitari in una prospettiva internazionale 238
Il confronto dei sistemi sanitari in una prospettiva internazionale 236
La spesa sanitaria: composizione ed evoluzione 235
I settori contigui alla sanità: struttura e performance delle imprese farmaceutiche, di dispositivi medici e delle farmacie in Italia 230
The impact of HTA and procurement practices on the selection and prices of medical devices 228
La spesa sanitaria: composizione ed evoluzione 227
Cost-effectiveness and net monetary benefit of Olaparib maintenance therapy versus no maintenance therapy after first-line platinum-based chemotherapy in newly diagnosed advanced BRCA1/2-mutated ovarian cancer in the Italian National Health Service 227
Politiche del farmaco: approfondimento sul Value Framework per i farmaci 225
A meta-analysis of MitraClip combined with medical therapy versus medical therapy alone for treatment of mitral regurgitation in heart failure patients 220
The invisible costs of obstructive sleep apnea (OSA): systematic review and cost-of-illness analysis 217
Implementation of value-based pricing for medicines 214
Cost-effectiveness analysis of HRD testing for previously treated patients with advanced ovarian cancer in Italy 210
L'attività sperimentale sui dispositivi medici 206
The impact of generic reference pricing in Italy, a decade on 206
Il confronto dei sistemi sanitari in una prospettiva internazionale 203
Il confronto dei sistemi sanitari in una prospettiva internazionale 199
La spesa sanitaria: composizione ed evoluzione 193
When peers count: the effects on integrated type II diabetes care of communication within general practitioner-only subgroups in interprofessional primary care teams 192
Cost-effectiveness analysis of pressure-controlled intermittent coronary sinus occlusion in elective percutaneous coronary intervention 190
The impact of generic reference pricing in Italy, a decade on 190
Mobile health divide between clinicians and patients in cancer care: results from a cross-sectional international survey 190
Early access programs for medicines: comparative analysis among France, Italy, Spain, and UK and focus on the Italian case 188
Cost-effectiveness of the coronary sinus Reducer and its impact on the healthcare burden of refractory angina patients 187
Economic impact of a more extensive use of FENO testing on the Italian population with asthma 182
The social burden and quality of life of patients with haemophilia in Italy 174
La spesa sanitaria: composizione ed evoluzione 172
The value of hearing aids for the Italian NHS: a cost-utility analysis 171
Multi-professional primary care units: what affects the clinical performance of Italian general practitioners? 171
Cost per responder of Adalimumab biosimilars MSB11022 and ABP 501 versus the originator and methotrexate in chronic plaque psoriasis 169
L’evoluzione del finanziamento dei farmaci in Italia 169
The simultaneous effects of pharmaceutical policies from payers' and patients' perspectives: Italy as a case study 166
Social/economic costs and quality of life in patients with haemophilia in Europe 164
What type of clinical evidence is needed to assess medical devices? 163
La spesa sanitaria: composizione ed evoluzione 163
Il settore dei dispositivi medici in Italia. L’impatto delle politiche pubbliche sulle performance delle imprese 162
The simultaneous effects of pharmaceutical policies from payers' and patients' perspectives: Italy as a case study 158
The simultaneous effects of pharmaceutical policies from payers’ and patients’ perspectives: Italy as a case study 154
Pharmaceutical pricing and managed entry agreements: An exploratory study on future perspectives in Europe 150
Social/economic costs and health-related quality of life in patients with Duchenne muscular dystrophy in Europe 145
Economic evaluation of two therapeutic sequences in the first-line treatment of moderate to severe active ulcerative rectocolitis in Italy 145
Elicitation of societal preferences for chronic lymphocytic leukemia’s treatments: a discrete choice experiment 142
Social economic costs, health-related quality of life and disability in patients with Cri Du Chat syndrome 137
La spesa sanitaria: composizione ed evoluzione 133
Exploring the potential of digital therapeutics: an assessment of progress and promise 131
Variations in non-prescription drug consumption and expenditure: determinants and policy implications 127
La spesa sanitaria: composizione ed evoluzione 124
La spesa sanitaria: composizione ed evoluzione 122
Use of resource modeling to quantify the organizational impact of subcutaneous formulations for the treatment of oncologic patients: the case of daratumumab in multiple myeloma 119
Health system quality and COVID-19 vaccination: a cross-sectional analysis in 14 countries 115
La spesa sanitaria: composizione ed evoluzione 114
Percutaneous mitral valve repair vs. stand-alone medical therapy in patients with functional mitral regurgitation and heart failure 107
The role of health systems in shaping vaccine decisions: Insights from Italy, Mexico, the United Kingdom, and the United States 107
Optimizing treatment sequencing in multiple myeloma: a novel model to predict survival outcomes 103
The economic burden of anesthetic-related adverse events: a systematic review and empirical analysis 102
Reflections on the importance of cost of illness analysis in rare diseases: a proposal 94
Individual and team performanc: issues around the role of attributes and relationships among peers 75
The relationship between trust and compliance in the Italian NHS: Results of the People's Voice Survey 66
Promoting healthy aging in a digital world: leveraging technology for enhanced elderly care and wellbeing 34
Implementing the EU HTA regulation and joint clinical assessment: a multi-stakeholder perspective from Italy 27
Organizational impacts of fixed-duration therapies for the management of patients with chronic lymphocytic leukemia in Italy 22
Totale 20.666
Salva come PNG Salva come JPEG
Categoria #
all - tutte 72.524
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 72.524
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022687 0 0 36 41 66 12 31 174 41 47 105 134
2022/20232.347 119 127 58 176 153 189 63 101 977 94 165 125
2023/20241.807 104 97 123 89 167 177 105 279 99 136 211 220
2024/20252.490 138 36 170 123 209 157 162 165 571 286 303 170
2025/20268.588 559 647 292 573 605 336 906 837 2.269 896 498 170
2026/2027785 285 456 44 0 0 0 0 0 0 0 0 0
Totale 20.666